Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 0.73 |
| ▸ | INSR | P06213 | 5/20 | 0.73 |
| ▸ | EGFR | P00533 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | PLK4 | O00444 | 1/20 | 0.73 |
| ▸ | BUB1B | O60566 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | NPM1 | P06748 | 1/20 | 0.73 |
| ▸ | FES | P07332 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | IGF1R | P08069 | 1/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.73 |
| ▸ | MET | P08581 | 1/20 | 0.73 |
| ▸ | ROS1 | P08922 | 1/20 | 0.73 |
| ▸ | FGR | P09769 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15977109 | 0.90 | ALK (0.80) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL14479209 | 0.89 | ALK (0.61) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL28337496 | 0.88 | ALK (0.76) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL28502216 | 0.87 | ALK (0.74) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL23637757 | 0.85 | ALK (0.87) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL14479213 | 0.85 | ALK (0.56) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL28516423 | 0.85 | ALK (0.71) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL21169823 | 0.85 | ALK (0.86) | ALKINSREGFRKCNH2PLK4 | |
| SCHEMBL19372641 | 0.85 | ALK (0.71) | ALKINSREGFRKCNH2PLK4 | |
| Ceritinib SCHEMBL29489147 | 0.85 | ALK (1.00) | ALKINSREGFRKCNH2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466943-B1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO LTD (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-10604505-B2 | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib | NATCO PHARMA LIMITED (IN) | 2020-03-31 | — | — | US | disclosed |
| EP-3466943-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-20190047983-A1 | MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | NATCO PHARMA LIMITED (IN) | 2019-02-14 | — | — | US | disclosed |
| WO-2017204445-A2 | PHARMACEUTICAL COMPOSITION INDUCING DECOMPOSITION OF ALK PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE COMPONENT | 한국화학연구원 | 2017-11-30 | — | — | WO | disclosed |
| WO-2017158619-A1 | A MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | NATCO PHARMA LIMITED (IN) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017041771-A1 | PROCESS FOR THE PREPARATION OF CERITINIB USING \"IN SITU\" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE | ZENTIVA, K.S. (CZ) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604505-B2 | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib | ALK, AURKA, MAP3K5 | ALK 1/4885INSR 1434/4885EGFR 4/4885 |
| US-20190047983-A1 | MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB | ALK, AURKA, MAP3K5 | ALK 1/4885INSR 1434/4885EGFR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.